Stockholm (HedgeNordic) – Rhenman & Partners is expanding its portfolio management team with the addition of Camilla Oxhamre Cruse as the fourth portfolio manager, with a primary focus on pharmaceutical development companies. Starting in early September, Cruse will join the four-member investment team led by founder and CIO Henrik Rhenman.

Cruse has spent the last ten years in London, most recently as a senior healthcare analyst and assistant portfolio manager at Newton Investment Management. Her career also includes a seven-and-a-half-year tenure at William Blair & Company as a senior research analyst covering the global healthcare sector. Prior to her time in London, Cruse was a senior equity analyst at Carnegie Investment Bank in Stockholm, focusing on healthcare. She holds a master’s degree in biochemistry from Lund University, a doctorate in medicine from Karolinska Institute, and an MBA from Hawaii Pacific University in the United States.

“Camilla’s long international background and broad expertise in the medical field and her experience in the financial markets will be a strong addition to our organization.”

Henrik Rhenman, founder and CIO at Rhenman & Partners.

“We are very pleased that Camilla will become part of Rhenman & Partners,” says Henrik Rhenman, founder and CIO at Rhenman & Partners. “Camilla’s long international background and broad expertise in the medical field and her experience in the financial markets will be a strong addition to our organization,” he continues. “Camilla will work closely with the entire investment team, focusing on the biotech and pharmaceutical sub-sectors where we continue to see great potential.” 

“It is a company that I have followed for a long time and that has impressed me with its in-depth fundamental analysis in the healthcare sector, integrity and skillful management, which has led to a long track record of positive returns.”

Camilla Oxhamre Cruse

“I look forward to joining Rhenman & Partners,” comments Camilla Oxhamre Cruse. “It is a company that I have followed for a long time and that has impressed me with its in-depth fundamental analysis in the healthcare sector, integrity and skillful management, which has led to a long track record of positive returns,” she adds. “I am really pleased to become part of the team and to be able to contribute with my many years of analytical experience of the global pharmaceutical sector.”

Cruse will work alongside portfolio managers Kaspar Hållsten, Hugo Schmidt, and Amennai Beyeen, under the leadership of CIO Henrik Rhenman, to manage the Rhenman Healthcare Equity L/S fund. Since its launch in mid-2009, the fund has delivered an annualized return of 16.6 percent for the share class represented in the Nordic Hedge Index. The fund has gained 17.1 percent in the first seven months of 2024.